全球灭活小儿麻痹病毒疫苗市场：现况分析与预测（2023-2030）

灭活小儿麻痹疫苗是预防小儿麻痹疾病的安全有效的疫苗。 小儿麻痹是由小儿麻痹病毒引起的高度传染性疾病，它会感染人类的免疫系统。 该疫苗含有灭活或 "灭活" 的小儿麻痹病毒株。 IPV 不是活病毒疫苗，不会引起小儿麻痹或其他疾病。 IPV 由死病毒颗粒製成，已被削弱到无法复製或引起感染的程度。 因此，即使对于免疫系统较弱的人来说也是安全的。 疫苗被注射到体内，刺激免疫系统产生抗体并抵抗病毒。 疫苗通常透过注射到手臂中来注射，例如接受化疗或服用免疫抑制剂的人。 政府和社区关于疫苗接种重要性的意识计划的激增等因素正在推动市场的发展。 例如，2020年，全球根除小儿麻痹倡议（GPEI）启动了对其根除小儿麻痹策略的审查，即《2022-2026年根除小儿麻痹策略》。 该策略为实现永久、永续的无脊灰病毒世界提供了路线图。 其他因素，例如医疗框架的进步以及公共当局、机构和医疗服务领域敏感领域的投机不断增加，正在推动预测期内的市场发展。 此外，对全球根除小儿麻痹的日益关注以及世界卫生组织（WHO）等组织推动的新的根除小儿麻痹措施的推出进一步支持了市场发展。 例如，2020 年，美国疾病管制与预防中心估计，全球83% 的1 岁以下婴儿在常规儿童免疫接种过程中接受了三剂或以上Pol3 疫苗接种，其中80% 的婴儿至少接受过一次完整疫苗接种(IPV1)。已接受至少两次分剂量 (IPV1)。

由于需要根除的脊髓灰质炎病例不断增加，製药公司提供的有效疫苗数量不断增加，全球灭活脊髓灰质炎病毒疫苗市场预计将稳定增长约5.1%。马苏。 例如，根据美国疾病管制与预防中心2022年8月的数据，灭活小儿麻痹疫苗（IPV）接种两剂后对麻痹性小儿麻痹有效率超过90%，接种三剂后有效率达99%至100%。是正确的。 已经引入了许多新疗法来治疗这种致命的脊髓灰质炎病毒。 其他几个因素，例如有前途的製药公司的建立、更好的治疗方法及其成本效益的引入以及政府举措，正在推动灭活脊髓灰质炎病毒疫苗的全球市场稳步发展。 例如，Serum Institute是一家成立于印度的疫苗製造商，也是全球最大的疫苗製造商之一。 我们生产多种疫苗，包括 IPV 疫苗。 IPV又称IPV-BB疫苗，以其优良的品质和性价比而闻名。 多年来，血清研究所经历了国内和国际市场的显着扩张。

依类型，市场分为人类二倍体细胞和猴肾细胞。 人类二倍体细胞部分在全球灭活小儿麻痹病毒疫苗市场中占有最大份额。 该细分市场占据市场主导地位，因为它是最有效、使用最广泛的疫苗。 人类二倍体细胞 (HDC) 疫苗是使用人类二倍体 (HDP) 细胞培养物生产的。 在明确动物细胞不适合生产小儿麻痹病毒后，开始发展这种小儿麻痹疫苗细胞系。 此类疫苗已获得授权并适用于世界各个地区。 例如，灭活（人类二倍体细胞）小儿麻痹疫苗Poliovax已获得美国食品药物管理局（FDA）的疫苗批准。 因此，由于上述原因，人类二倍体细胞细分市场将在2022年占据重要的市场份额。

根据销售管道，市场分为公共部门和私部门。 预计私营部门在预测期内将占据很大的市场份额，因为私人健康保险涵盖所有免疫接种，包括六个月以下婴儿的免疫接种。 除此之外，脊髓灰质炎病例数量和工作量的不断增加导致医院患者数量增加，并推动了这一领域的成长。 经过不懈努力，全世界已成功减少小儿麻痹的传播。 据世界卫生组织 (WHO) 称，如果不采取这些措施，到 2023 年 10 月，目前行走的超过 2,000 万人将陷入瘫痪。 光是 2020 年，在疫苗接种活动中系统性地施用维生素 A 就避免了 150 万名儿童死亡。 非洲成为 2020 年第五个宣布消灭野生小儿麻痹的地区。 因此，在分销管道中，私人类别预计在预测期内录得较高的复合年增长率。

为了更了解灭活小儿麻痹疫苗的市场介绍，市场有北美（美国、加拿大等北美地区）、欧洲（德国、英国、法国、西班牙、义大利等欧洲地区）、亚洲太平洋地区（中国、日本、印度、亚太地区其他地区）和世界其他地区。 由于小儿麻痹病例持续发生、疫苗接种率飙升以及对开发有效疗法的投资不断增加，2022年全球灭活小儿麻痹病毒疫苗市场将由北美主导。 政府机构已启动小儿麻痹宣传计划，为患者提供有效的治疗。 例如，根据 Frontiers Media S.A. 2020 年 7 月发表的一篇文章，疫苗的开发、许可和推出是作为大规模系统免疫计划的一部分，该计划开始解决北美的健康差距。 因此，2022年北美将占据很大的市场份额。

目录

第一章市场介绍

• 市场定义
• 主要目标
• 利害关係人
• 限制

第二章研究方法或假设

• 调查过程
• 调查方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对全球灭活小儿麻痹病毒疫苗市场的影响

第六章全球灭活小儿麻痹病毒疫苗市场收入（2020-2030）

第 7 章按类型划分的市场洞察

• 人类二倍体细胞
• 猴肾细胞

第 8 章依通路划分的市场洞察

• 公开
• 私人

第 9 章按地区划分的市场洞察

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区

第十章全球灭活小儿麻痹病毒疫苗市场动态

• 市场驱动因素
• 市场挑战
• 影响分析

第 11 章灭活小儿麻痹病毒疫苗的全球市场机会

第十二章灭活小儿麻痹病毒疫苗的全球市场趋势

第十三章需求方与供给方分析

• 需求方分析
• 供给面分析

第14章价值链分析

第15章竞争场景

• 竞争状况
  • 波特五力分析

第十六章公司简介

• Bharat Biotech.
• BIO-MED
• Serum Institute of India Pvt. Ltd.
• Kedrion
• GSK plc.
• Bilthoven Biologicals
• Merck & Co., Inc.
• Pfizer Inc.
• Cadila Pharmaceuticals
• Berna Biotech Pharma GmbH

第十七章免责声明

The inactivated polio vaccine is a safe and effective vaccine to prevent polio disease. Polio is a highly contagious disease caused by poliovirus that infects the human immune system. It contains killed or "inactivated" poliovirus strains. IPV is not a live virus vaccine, so it cannot cause polio or any other illness. It is made from killed virus particles, which are then weakened to the point where they cannot replicate or cause infection. This makes it safe for people with weakened immune systems. The vaccine is injected into the body to stimulate the immune system to make antibodies to fight off the virus. The vaccine is usually given through an injection into the arm, such as those undergoing chemotherapy or taking immunosuppressive drugs, to receive the vaccine. Factors such as a surge in government and community awareness programs concerning the significance of vaccination are driving the market. For instance, in 2020, the Global Polio Eradication Initiative (GPEI) launched a review of the strategy polio eradication strategy 2022 - 2026 for polio eradication. The strategy provides a roadmap for achieving a lasting and sustainable world free of poliovirus. Other factors, including advancements in medical care framework, and expanded speculations from the public authority, public, and confidential areas in medical services divisions are driving the development of the market during the forecast period. Moreover, the rising spotlight on eliminating polio globally and the introduction of new polio-eradicating initiatives driven by associations like the World Health Organization (WHO) further reinforce market development. For instance, in 2020, the Centers for Disease Control and Prevention estimated global coverage with more than 3 doses of Pol3 for infants <1 year of age vaccinated during routine childhood immunizations with 83% of children receiving more than 1 full dose (IPV1) and 80% receiving more than 2 fractional doses (IPV1).

The Global Inactivated Poliovirus Vaccine Market is expected to grow at a steady rate of around 5.1% owing to the increase in effective vaccines offered by pharmaceutical companies due to the constant growth in polio cases which needs to be controlled. For instance, according to the Centers for Disease Control and Prevention in August 2022, two doses of inactivated polio vaccine (IPV) were 90% effective or more against paralytic polio; three doses were 99% to 100% effective. Many new therapies are being introduced to treat this deadly polio virus. Several other factors, such as the establishment of potential pharmaceutical companies, the introduction of better therapeutics and their cost-effectiveness, and government initiatives are also driving this market of global inactivated poliovirus vaccines at a steady rate. For instance, Serum Institute is a vaccine manufacturer established in India and is one of the largest vaccine manufacturers in the world. It manufactures a variety of vaccines, including the IPV vaccine. The IPV, also known as the IPV-BB vaccine, is renowned for its superior quality and cost-effectiveness. Over the years, Serum Institute has experienced significant market expansion, both domestically and internationally.

Based on type, the market is bifurcated into human diploid cells and monkey kidney cells. The human diploid cell segment held the maximum share in the global market of inactivated poliovirus vaccines 2022. This segment dominated the market because of the higher efficacy. These are the most widely used type of vaccine. Human diploid cell (HDC) vaccines are produced using human diploid (HDP) cell cultures. The development of this cell line for polio vaccines began when it became apparent that animal cells were unsuitable for producing polioviruses. Various regions of the world have licensed and adapted the usage of such vaccines. For instance, the Poliovirus vaccine Inactivated (human diploid cell) vaccine Poliovax has been granted a vaccine license in the U.S. by the Food and Drug Administration (FDA). Hence, for the above reasons, the human diploid cell segment held a significant market share in 2022.

Based on the distribution channel, the market is bifurcated into public and private. The private segment is expected to hold a significant share of the market in the forecast period owing to private health insurance providing coverage for all vaccinations, including vaccinations for infants under six months of age. Apart from this, the constant number of cases of polio and workload is boosting the hospital's patient load and impelling this segment's growth. With constant efforts, the world has seen success in controlling polio spread to a major extent. For instance, according to the World Health Organization (WHO), in October of 2023, over 20 million people walking today would otherwise be paralyzed. Vaccine-systematic vitamin A administration during immunization activities has prevented an estimated 1,500,000 childhood deaths in 2020 alone. Africa became the 5th region to be declared wild Polio-free in 2020. Hence, amongst distribution channels, the private category is expected to witness a higher CAGR during the forecast period.

For a better understanding of the market adoption of inactivated poliovirus vaccine, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global inactivated poliovirus vaccine market in 2022 due to the constant polio cases, surge in vaccination rate, and rising investments in developing effective therapeutics. Government organizations are initiating polio awareness programs to provide efficient care to patients. For instance, according to an article published in Frontiers Media S.A. in July 2020, vaccines were developed, licensed, and introduced as part of large systematic immunization programs that began to address health disparities in North America. Thus, North America held a significant share of the market in the year 2022.

Some of the major players operating in the market include: Bharat Biotech.; BIO-MED; Serum Institute of India Pvt. Ltd.; Kedrion; GSK plc.; Bilthoven Biologicals; Merck & Co.; Inc.; Pfizer Inc.; Cadila Pharmaceuticals; Berna Biotech Pharma GmbH.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Global Inactivated Poliovirus Vaccine Market
• 2.2. Research Methodology of the Global Inactivated Poliovirus Vaccine Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET

6 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Human Diploid Cell
• 7.2. Monkey Kidney Cell

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Public
• 8.2. Private

9 MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET OPPORTUNITIES

12 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

• 15.1. Competitive Landscape
  • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

• 16.1. Bharat Biotech.
• 16.2. BIO-MED
• 16.3. Serum Institute of India Pvt. Ltd.
• 16.4. Kedrion
• 16.5. GSK plc.
• 16.6. Bilthoven Biologicals
• 16.7. Merck & Co., Inc.
• 16.8. Pfizer Inc.
• 16.9. Cadila Pharmaceuticals
• 16.10. Berna Biotech Pharma GmbH

17 DISCLAIMER